Bioefficacy of budesonide loaded crosslinked polyeletrolyte microparticles in rat model of induced colitis

Journal of Drug Targeting

Volumn 17, Issue 10, 2009, Pages 788-802

  Crcarevska, M Simonoska ^a   Dodov, M Glavas ^a   Petrusevska, G ^b   Gjorgoski, I ^c   Goracinova, K ^a  

^a SS Cyril and Methodius University Faculty of Pharmacy   (Macedonia)

^b SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

^c SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

Author keywords

Alginate; chitosan; controlled release; microparticles; oral drug delivery

Indexed keywords

ALGINIC ACID; ANTIINFLAMMATORY AGENT; BUDESONIDE; CALCIUM CHLORIDE; CHITOSAN; CROSS LINKING REAGENT; ELECTROLYTE; GLUCURONIC ACID; HEXURONIC ACID; METHYLMETHACRYLATE METHACRYLIC ACID COPOLYMER; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; MICROSPHERE; POLYMETHACRYLIC ACID DERIVATIVE; TRINITROBENZENESULFONIC ACID;

ANIMAL; ARTICLE; CHEMISTRY; COLITIS; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG DELIVERY SYSTEM; MALE; RAT; WISTAR RAT;

ALGINATES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CALCIUM CHLORIDE; CHITOSAN; COLITIS; CROSS-LINKING REAGENTS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ELECTROLYTES; GLUCURONIC ACID; HEXURONIC ACIDS; MALE; MICROSPHERES; POLYMETHACRYLIC ACIDS; RATS; RATS, WISTAR; TRINITROBENZENESULFONIC ACID;

EID: 77949894716     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903161310     Document Type: Article

References (65)

1. Bernkop-Schnürch A, Weithaler A, Albrecht K, Greimel A. (2006). Thiomers: preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system. Int J Pharm, 317(1), 76 – 81.
2. Brogden RN, McTavish D. (1992). Budesonide: an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs, 44 (3), 375 – 407.
3. Chickering DE, Mathiowitz E. (1995). Bioadhesive microspheres: I. A novel electrobalance-based method to study adhesive interactions between individual microspheres and intestinal mucosa. J Control Release, 34, 251 – 261.
4. Chickering DE, Jacob P, Mathiowitz E. (1992). A tensile technique to evaluate the interaction of bioadhesive microspheres with intestinal mucosa. Proc Int Symp Control Release Bioact Mater, 19, 88 – 89.
5. Coppi G, Iannuccelli V, Leo E, Bernabei MT, Cameroni R. (2001). Chitosan-alginate microparticles as a protein carrier. Drug Dev Ind Pharm, 27 (5), 393 – 400.
6. Coppi G, Iannuccelli V, Bernabei MT, Cameroni R. (2002). Alginate microparticles for enzyme peroral administration. Int J Pharm, 242 (1-2), 263 – 266.
7. Davis SS, Hardy JG, Fara JW. (1986). Transit of pharmaceutical dosage forms through the small intestine. Gut, 27, 886 – 892.
8. Deacon MP, McGurk M, Roberts CJ, Williams PM, Tendler SJB, Davies MC, Davis SS, Hardings SE. (2000). Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems. Biochem J, 348, 557 – 563.
9. Edsbäcker S, Bengtsson B, Larsson P, Lundin P, Nilsson A, Ulmius J, Wollmer P. (2003). A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsule. Aliment Pharmacol Ther, 17, 525 – 636.
10. Ewe K, Schwartz S, Petersen S, Press AG. (1999). Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease. Dig Dis Sci, 44, 1434 – 1439.
11. Fallingborg J, Pedersen P, Jacobsen BA. (1998). Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn’s disease. Dig Dis Sci, 43, 702 – 705.
12. Fedorak RN, Bistritz L. (2005). Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliver Rev, 57, 303 – 316.
13. Fiebrig I, Harding SE, Davis SS. (1994). Sedimentation analysis of potential interactions between mucins and a putative bioadhesive polymer. Prog Colloid Polym Sci, 94, 66 – 73.
14. Fiebrig I, Harding SE, Rowe AJ, Hyman SC, Davis SS. (1995). Transmission electron microscopy on pig gastric mucin and its interactions with chitosan. Carbohydr Polym, 28, 239 – 244.
15. George M, Abraham TE. (2006). Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan—a review. J Control Rel, 114, 1 – 14.
16. Glavas Dodov M, Calis S, Simonoska M, Goracinova K. (2006). Formulation and evaluation of 5-FU loaded chitosan/alginate microparticles prepared by spray-drying. 13th International Pharmaceutical Technology Symposium, Turkey.
17. Glavas Dodov M, Hincal AA, Calis S, Simonoska Crcarevska M, Geskovski N, Goracinova K. (2007). Spray-dried chitosan-Ca-alginate microparticles for colon delivery of 5-FU. Maced Pharm Bull, 53 (1,2), 45 – 46.
18. Glavas Dodov M, Hincal AA, Calis S, Simonoska Crcarevska M, Geskovski N, Goracinova K. (2008). Chitosan-Ca-Alginate microparticles loaded with HPMCP HP55 coated 5-FU: physical characterization. 6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical technology, Spain.
19. Gombotz WR, Wee SF. (1998). Protein release from alginate matrices. Adv Drug Deliver Rev, 31, 267 – 285.
20. Goracinova K. (2005). Formulation and preparation of spray-dried alginate-Ca microparticles. Patent No. MP/MK/05/01/FF/BE/01/IP.
21. Goracinova K, Mladenovska K, Glavas Dodov M, Simonoska M. (2005). Optimizing formulation factors in preparation of microparticles by spray-drying process. Abstractbook of 15th International Symposium on Microencapsulation, Italy.
22. Hardy FH, Davis SS, Khosla R, Robertson CS. (1988). Gastrointestinal transit of small tablets in patients with ulcerative colitis. Int J Pharm, 48, 79 – 82.
23. Hebden JM, Blackshaw PE, Perkins AC, Wilson CG, Spiller RC. (2000). Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther, 14, 155 – 161.
24. Hejazi R, Amiji M. (2003). Chitosan-based gastrointestinal delivery systems. J Control Rel, 89, 151 – 165.
25. Huanbutta K, Luangtana-Anan M, Sriamornsaki P, Limmatvapirat S, Puttipipatkhachorn S, Nunthanid J. (2008). Factors affecting preparations of chitosan microcapsules for colonic drug delivery. J. Metals, Mater. Mine, 18 (2), 79 – 83.
26. Illum L. (1998). Chitosan and its use as a pharmaceutical excipient. Pharm Res, 15, 1326 – 1331.
27. Lamprecht A, Schafer U, Lehr CM. (2000). Microparticle targeting to the inflamed colonic mucosa for the treatment of inflammatory bowel disease: in vivo results from rat. AAPS Pharm Sci, 2, 1930. [abstract]
28. Lamprecht A, Schafer U, Lehr CM. (2001a). Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res, 18, 788 – 793.
29. Lamprecht A, Ubrich N, Yamamoto H, Scheafer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM. (2001b). Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther, 299, 775 – 781.
30. Lamprecht A, Stallmach A, Kawashima Y, Lehr CM. (2002). Carrier systems for the treatment of inflammatory bowel disease. Drugs Future, 27, 961 – 971.
31. Loke WK, Lau SK, Yong LL, Khor E, Sum CK. (2000). Wound dressing with sustained anti-microbial capability. J Biomed Mater Res, 53, 8 – 17.
32. Lorenzo-Lamosa ML, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. (1998). Design of microencapsulated chitosan microspheres for colonic drug delivery. J Control Release, 52, 109 – 118.
33. Martinac A, Filipović-Grčić J, Voinovich D, Perissutti B, Franceschinis E. (2005). Development and bioadhesive properties of chitosan-ethylcellulose microspheres for nasal delivery. Int J Pharm, 291 (1, 2), 69 – 77.
34. McConnell EL, Fadda HM, Basit AW. (2008). Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm, 364, 213 – 226.
35. Meissner Y, Pellequer Y, Lamprecht A. (2006). Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. Int J Pharm, 316, 138 – 143.
36. Mi FL, Shyu SS, Wu YB, Lee ST, Shyong JY, Hunag RN. (2001). Fabrication and characterization of a sponge-like asymmetric chitosan membrane as a wound dressing. Biomaterials, 22, 165 – 173.
37. Mladenovska K, Raicki RS, Janevik EI, Ristoski T, Pavlova MJ, Kavrakovski Z, Dodov MG, Goracinova K. (2007). Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles. Int J Pharm, 342, 124 – 136.
38. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MY, Wallace JL. (1989). Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology, 96, 795 – 803.
39. Nakase H, Okazaki K, Tabata Y, Uose S, Ohana M, Uchida K, Matsushima Y, Kawanami C, Oshima C, Ikada Y, Chiba T. (2000). Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J Pharmacol Exp Ther, 292, 15 – 21.
40. NATO Science for Peace Project 978023. (2006). Influence of biopolymer interactions on the drug delivery from chitosan-alginate colloidal carrier systems. [Report]
41. Nilsson M, Edsbacker S, Conradson TB. (1992). Rectal and oral bioavailability of budesonide in man. Hell J Gastroenterol, 5 (Suppl.), 297.
42. Onishi H, Machida Y. (2008). In vitro and in vivo evaluation of microparticulate drug delivery systems composed of macromolecular prodrugs. Molecules, 13, 2136 – 2155.
43. Onishi H, Oosegi T, Machida Y. (2008). Efficacy and toxicity of Eudragit-coated chitosan–succinyl-prednisolone conjugate microspheres using rats with 2,4,6-trinitrobenzenesulfonic acid-induced colitis. Int J Pharm, 358, 296 – 302.
44. Oosegi T, Onishi H, Machida Y. (2008). Gastrointestinal distribution and absorption behavior of eudragit-coated chitosan–prednisolone conjugate microspheres in rats with TNBS-induced colitis. Int J Pharm, 348, 80 – 88.
45. Press AG, Hauptmann IA, Hauptmann L, Fuchs B, Fuchs M, Ewe K, Ramadori G. (1998). Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther, 12, 673 – 678.
46. Rodriguez M, Antonez JA, Taboada C, Seijo B, Torres D. (2001). Colon-specific delivery of budesonide from microencapsulated cellulosic cores: evaluation of the efficacy against colonic inflammation in rats. J Pharm Pharmacol, 53(9), 1207 – 1215.
47. Rubinstein A. (1995). Approaches and opportunities in colon-specific drug delivery. Crit Rev Ther Drug Carrier Syst, 12, 101 – 149.
48. Simonoska M, Glavas-Dodov M, Dimitrovska A, Goracinova K. (2006). Microparticle design for colon delivery of budesonide. 13th International Pharmaceutical Technology Symposium, Turkey.
49. Simonoska M, Glavas-Dodov M, Goracinova K. (2007). Enteric coated chitosan-Ca-alginate microparticles for colon drug delivery. Maced Pharm Bull, 53 (1,2), 55 – 56.
50. Simonoska Crcarevska M, Goracinova K, Glavas Dodov M, Steffansen B. (2007). Uptake studies of chitosan-Ca-alginate microparticles loaded with 5-FU in human intestinal cell lines. Maced Pharm Bull, 53 (1,2), 24.
51. Simonoska Crcarevska M, Glavas Dodov M, Goracinova K. (2008). Chitosan coated Ca-alginate microparticles loaded with budesonide for delivery to the inflamed colonic mucosa. Eur J Pharm Biopharm, 68 (3), 565 – 578.
52. Tabata Y, Ikada Y. (1988). Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials, 9, 356 – 362.
53. Tabata Y, Ikada Y. (1990). Phagocytosis of polymer microspheres by macrophages. Adv Polym Sci, 94, 107 – 141.
54. Tabata Y, Inoue Y, Ikada Y. (1996). Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine, 14, 1677 – 1685.
55. Tirosh B, Rubinstein A. (1998). Migration of adhesive and nonadhesive particles in the rat intestine under altered mucus secretion conditions. J Pharm Sci, 87, 453 – 456.
56. Tozaki H, Fujita T, Komoike J, Kim SI, Terashima H, Muranishi S, Okabe S, Yamamoto A. (1999). Colon-specific delivery of budesonide with azopolymer-coated pellets: therapeutic effects of budesonide with a novel dosage form against 2,4,6,-trinitrobenzensulphonic acid-induced colitis in rats. J Pharm Pharmacol, 51, 257 – 261.
57. Tozaki H, Odoriba T, Okada N, Fujita T, Terabe A, Suzuki T, Okabe S, Muranishi S, Yamamoto A. (2002). Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J Control Release, 82 (1), 51 – 61.
58. Van Der Lubben IM, Konings FA, Borchard G, Verhoef JC, Junginger HE. (2001). In vivo uptake of chitosan microparticles by murine Peyer’s patches: visualization studies using confocal laser scanning microscopy and immunohistochemistry. J Drug Target, 9, 39 – 47.
59. Varum FJO, McConnell EL, Sousa JJS, Veiga F, Basit AW. (2008). Mucoadhesion and the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst, 25 (3), 207 – 258.
60. Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, Thomforde GM. (1992). Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology, 102, 102 – 108.
61. Watts PJ, Barrow L, Steed KP, Wilson CG, Spiller RC, Melia CD, Davies MC. (1992). The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis. Int J Pharm, 87, 215 – 221.
62. Wittaya-areekul S, Kruenate J, Prahsarn C. (2006). Preparation and in vitro evaluation of mucoadhesive properties of alginate/chitosan microparticles containing prednisolone. Int J Pharm, 312, 113 – 118.
63. Yamada T, Marshall S, Specian RD, Grisham MB. (1992). A comparative analysis of two models of colitis in rats. Gastroenterology, 102, 1524 – 1534.
64. Yan X-L, Khor E, Lim L-Y. (2001). Chitosan-alginate films prepared with chitosans of different molecular weights. J Biomed Mater Res, 58 (4), 358 – 365.
65. Yue G, Sun FF, Dunn C, Yin K, Wong PYK. (1996). The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats. J Pharmacol Exp Ther, 276, 265 – 270.